Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Colorectal Neoplasms 150Stomach Neoplasms 52Neoplasms 49Pancreatic Neoplasms 41Neoplasm Metastasis 32Squamous Cell Carcinoma of Head and Neck 26Head and Neck Neoplasms 25Esophageal Neoplasms 24Colonic Neoplasms 22Rectal Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Breast Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 19Esophageal Squamous Cell Carcinoma 15Adenocarcinoma 14Adenocarcinoma Of Esophagus 12Cholangiocarcinoma 11Biliary Tract Neoplasms 11Ovarian Neoplasms 9Triple Negative Breast Neoplasms 7Gallbladder Neoplasms 7Carcinoma, Hepatocellular 7Carcinoma 7Urinary Bladder Neoplasms 6Sarcoma 6Keratosis, Actinic 6Gastrointestinal Neoplasms 6Endometrial Neoplasms 6Carcinoma, Squamous Cell 6Advanced Solid Tumors 6

Interventions

pembrolizumab 51Nivolumab 27Gemcitabine 23atezolizumab 19Cisplatin 18Carboplatin 18enfortumab vedotin 15avelumab 15Mitomycin 14Docetaxel 8Ipilimumab 7Paclitaxel 6Injections 5Cyclophosphamide 5vinflunine 4toripalimab 4tislelizumab 4lenvatinib 4fludarabine 4epacadostat 4Pemetrexed 4130-nm albumin-bound paclitaxel 4sacituzumab govitecan 3disitamab vedotin 3Rogaratinib 3Interleukin-2 3ALT-803 3vofatamab 2valrubicin 2rucaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Transitional Cell × Fluorouracil × Clear all
NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT03197571 2025-02-21

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡